Matrix metalloproteinase 12 is an independent prognostic factor predicting postoperative relapse of conventional renal cell carcinoma – a brief report

This article was originally published here

Oncol cell (Dordr). December 11, 2021. doi: 10.1007 / s13402-021-00650-9. Online ahead of print.


OBJECTIVE: Approximately 15% of clinically localized conventional renal cell carcinomas (cRCCs) metastasize within 5 years of follow-up. Sarcomatous cRCC is a highly malignant cancer of the kidney. The aim of our study was to identify biomarkers to estimate the postoperative progression of CRCc.

METHODS: Global gene expression analysis based on RCC DNA microarrays with and without sarcomatous changes revealed that high expression of MMP12 was associated with sarcomatous histology. In addition, we analyzed the expression of MMP12 using a multi-tissue matrix comprising 736 cRCC patients without metastasis at the time of surgery. The median duration of follow-up was 66 ± 29 months.

RESULTS: Immunohistochemistry revealed expression of MMP12 in 187 of 736 cRCCs with good follow-up data. A subsequent Kaplan-Meier analysis revealed that patients with MMP12 positive tumors had significantly shorter tumor-free survival (p

CONCLUSIONS: MMP12 can serve as a biomarker to estimate postoperative relapse of CRCC and as a possible target for penfluridol treatment.

PMID: 34894337 | DOI: 10.1007 / s13402-021-00650-9

Source link

About Florence L. Silvia

Check Also

Conduent Named a Leader in Everest Group’s 2022 PEAK Matrix® Healthcare Payment Operations Assessment

FLORHAM PARK, NJ, May 05, 2022 (GLOBE NEWSWIRE) — Incorporated Duct CNDTa business process services …